Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...
A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...
Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...
The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...
The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the ...
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
This comes as the Medicines and Healthcare Products Regulatory Agency (MHRA) said in August the drug, Donanemab, manufactured by pharmaceutical giant Eli Lilly, could be licensed for use in the UK.